Corosolic acid inhibits metastatic response of human renal cell carcinoma cells by modulating ERK/MMP2 signaling

Abstract

AbstractCorosolic acid (CA), a plant‐derived pentacyclic triterpenoid, has potent anti‐inflammatory, anti‐metabolic, and anti‐neoplastic actions against a variety of human cancers. However, the specific mechanism by which CA inhibits the progression of renal cell carcinoma (RCC) is yet unclear. We found that CA (≤8 μM) had no influence on either the growth or viability of RCC cell lines (786‐O, ACHN, and Caki‐1) or normal HK2 cells. However, in a dose‐dependent manner, CA prevented the invasion and migration of RCC cells. Human protease array analysis showed that CA reduced MMP2 expression. At increasing concentrations of CA, the expression of MMP2 was dose‐dependently reduced, as shown by western blot and RT‐PCR analyses as well as immunofluorescence staining. CA also stimulated ERK1/2 phosphorylation in 786‐O and Caki‐1 cells. Transfection of CA‐treated RCC cells with siRNA‐ERK restored MMP2 protein expression and the motility and invasion capabilities of RCC cells. Molecular docking study results showed that CA and MMP2 interact strongly. These findings elucidate the mechanism by which CA prevents RCC cells from migrating and invading, and these findings indicate that CA may be a potential anti‐metastatic therapy for RCC.